domingo, 26 de julio de 2015

Genomics|Genetic Testing|Guidelines: CANCER

Genomics|Genetic Testing|Guidelines

Genomics & Health Impact Update banner with DNA in background

Genetic Testing

Guidelines, Policies and Recommendations in Genomics

We provide on an ongoing basis an updated list of guidelines, policies and recommendations  on genomic research and practice, as provided by professional organizations, federal advisory groups, expert panels and policy groups.  The list is arranged by topics, year of publication and recommending organization. The list may not include all relevant recommendations. The listing of the recommendations should not be construed as an endorsement by CDC. 

Cancer



GuidelineOrganizationPublished
Guidelines for surveillance of individuals with constitutional mismatch repair-deficiency proposed by the European Consortium "Care for CMMR-D" (C4CMMR-D)External Web Site IconEuropean Consortium "Care for CMMR-D" (C4CMMR-D)2015
Referral indications for cancer predisposition assessmentExternal Web Site IconAmerican College of Medical Genetics and Genomics,External Web Site Icon National Society of Genetic CounselorsExternal Web Site Icon2015
Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice GuidelinesExternal Web Site IconAmerican Society of Clinical Oncology,External Web Site IconEuropean Society for Medical OncologyExternal Web Site Icon2015
Genetic testing and management of individuals genetically at-risk of cutaneous melanomaExternal Web Site IconExpert group2015
Lynch syndrome: A primer for urologists and panel recommendationsExternal Web Site IconExpert group2015
Updated UK Recommendations for HER2 assessment in breast cancerExternal Web Site IconNational Coordinating Committee for Breast PathologyExternal Web Site Icon2015
Biomarker testing in colorectal carcinoma - updateExternal Web Site IconSpanish Society of Pathology, Spanish Society of Medical Oncology2015
Endometrial cancer: a review and current management strategies: part IExternal Web Site IconSociety of Gynecologic Oncology Clinical Practice CommitteeExternal Web Site Icon2014
Genetic testing for inherited colorectal cancer (Lynch syndrome, familial adenomatous polyposis, and MYH-associated polyposis).External Web Site IconAmerican College of Medical Genetics and GenomicsExternal Web Site Icon2014
Collection and use of a cancer family health history for oncology providersExternal Web Site IconAmerican Society of Clinical OncologyExternal Web Site Icon2014
Disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastasesExternal Web Site IconAmerican Society of Clinical OncologyExternal Web Site Icon2014
Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancerExternal Web Site IconAmerican Society of Clinical OncologyExternal Web Site Icon2014
Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/InternatExternal Web Site IconAmerican Society of Clinical OncologyExternal Web Site Icon2014
Human epidermal growth factor receptor 2 testing in breast cancerExternal Web Site IconAmerican Society of Clinical Oncology,External Web Site IconCollege of American PathologistsExternal Web Site Icon2014
RAS testing of colorectal carcinomaExternal Web Site IconAssociation of Clinical Pathologists Molecular Pathology and Diagnostics GroupExternal Web Site Icon2014
Testing of ALK Gene Rearrangement in Lung CancerExternal Web Site IconCardiopulmonary Pathology Study Group of the Korean Society of PathologistsExternal Web Site Icon2014
Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers - 2014 updateExternal Web Site IconEuropean Group on Tumor MarkersExternal Web Site Icon2014
Guidance for laboratories performing molecular pathology for cancer patientsExternal Web Site IconEuropean Society of Pathology Task Force on Quality Assurance in Molecular PathologyExternal Web Site Icon2014
Does PCA3 testing for the diagnosis and management of prostate cancer improve patient health outcomes?External Web Site IconEvaluation of Genomic Applications in Practice and PreventionExternal Web Site Icon2014
Recommendations for analyzing and reporting TP53 gene variants in the high-throughput sequencing eraExternal Web Site IconExpert group2014
Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 yearsExternal Web Site IconInternational BFM Group (iBFM) Study Group Chronic Myeloid Leukaemia CommitteeExternal Web Site Icon2014
Diagnosis and management of hereditary colorectal cancer - summarized from JSCCR Guidelines 2012 for the Clinical Practice of Hereditary Colorectal CancerExternal Web Site IconJapanese Society for Cancer of the Colon and RectumExternal Web Site Icon2014
Genetic/familial high-risk assessment: breast and ovarian, version 1.2014External Web Site IconNational Comprehensive Cancer NetworkExternal Web Site Icon2014
Diagnosis, treatment and follow-up of hairy cell leukaemiaExternal Web Site IconSFH (French Society of Haematology)External Web Site Icon2014
Guidelines for biomarker testing in metastatic melanoma: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.External Web Site IconSpanish Society of Pathology, Spanish Society of Medical Oncology2014
Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutationsExternal Web Site IconUS Food and Drug AdministrationExternal Web Site Icon2014
FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutationExternal Web Site IconUS Food and Drug AdministrationExternal Web Site Icon2014
Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-society Task Force on colorectal cancerExternal Web Site IconUS Multi-society Task Force on colorectal cancer2014
Summaries for patients: assessing the genetic risk for BRCA-related breast or ovarian cancer in womenExternal Web Site IconUS Preventive Services Task ForceExternal Web Site Icon2014
American College of Medical Genetics and Genomics technical standards and guidelines: Microarray analysis for chromosome abnormalities in neoplastic disordersExternal Web Site IconAmerican College of Medical Genetics and GenomicsExternal Web Site Icon2013
Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline.External Web Site IconAmerican Society of Clinical OncologyExternal Web Site Icon2013
Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms: a report of the Association for Molecular PathologyExternal Web Site IconAssociation for Molecular PathologyExternal Web Site Icon2013
Evaluation of clinical validity and utility of actionable molecular diagnostic tests in adult oncology External Web Site IconCenter for Medical Technology PolicyExternal Web Site Icon2013
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular PathologyExternal Web Site IconCollege of American Pathologists,External Web Site IconInternational Association for the Study of Lung Cancer,External Web Site Icon Association for Molecular PathologyExternal Web Site Icon2013
Informing family members of individuals with Lynch syndrome: a guideline for clinical geneticistsExternal Web Site IconDutch Society for Clinical Genetics2013
Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?External Web Site IconEvaluation of Genomic Applications in Practice and PreventionExternal Web Site Icon2013
Canadian guideline on genetic screening for hereditary renal cell cancersExternal Web Site IconKidney Cancer Research Network of Canada Genetics InitiativeExternal Web Site Icon2013
EGFR Mutation Testing in Lung CancerExternal Web Site IconKorean Cardiopulmonary Pathology Study Group2013
Clinical management of Lynch syndrome (HNPCC)External Web Site IconMallorca GroupExternal Web Site Icon2013
EGFR-TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancerExternal Web Site IconNational Institute for Health and Care ExcellenceExternal Web Site Icon2013
Everolimus in combination with exemestane for treating advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapyExternal Web Site IconNational Institute for Health and Care ExcellenceExternal Web Site Icon2013
Familial breast cancer: Classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancerExternal Web Site IconNational Institute for Health and Care ExcellenceExternal Web Site Icon2013
Familial breast cancer: summary of updated NICE guidanceExternal Web Site IconNational Institute for Health and Care ExcellenceExternal Web Site Icon2013
Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and MammostratExternal Web Site IconNational Institute for Health and Care ExcellenceExternal Web Site Icon2013
Intraoperative tests (RD-100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancerExternal Web Site IconNational Institute for Health and Care ExcellenceExternal Web Site Icon2013
Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanomaExternal Web Site IconNational Institute for Health and Care ExcellenceExternal Web Site Icon2013
Risk assessment and genetic counseling for hereditary breast and ovarian cancerExternal Web Site IconNational Society of Genetic CounselorsExternal Web Site Icon2013
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013External Web Site IconSt Gallen International Breast Cancer Conference (2013) Expert PanelExternal Web Site Icon2013
BRAF mutation testing algorithm for vemurafenib treatment in melanomaExternal Web Site IconUK Expert Panel2013
BRCA-related Cancer: Risk Assessment, Genetic Counseling and Genetic TestingExternal Web Site IconUS Preventive Services Task ForceExternal Web Site Icon2013
Breast Cancer: Medications for Risk ReductionExternal Web Site IconUS Preventive Services Task ForceExternal Web Site Icon2013
Lung Cancer: ScreeningExternal Web Site IconUS Preventive Services Task ForceExternal Web Site Icon2013
Levels of evidence and clinical utility of prognostic and predictive candidate brain tumor biomarkersExternal Web Site IconVienna Comprehensive Cancer Center Central Nervous System Unit, Neurooncology Taskforce2013
Management of patients with colon and rectal cancerExternal Web Site IconEuropean Society for Medical OncologyExternal Web Site Icon2012
Biomarker testing in colorectal carcinoma External Web Site IconSpanish Society of Pathology, Spanish Society of Medical Oncology2012
UK NEQAS for Molecular Genetics scheme for gastrointestinal stromal tumourExternal Web Site IconUnited Kingdom National External Quality Assessment ServiceExternal Web Site Icon2012
Screening for ovarian cancerExternal Web Site IconUS Preventive Services Task ForceExternal Web Site Icon2012
Can tumor gene expression profiling improve outcomes in patients with breast cancer?External Web Site IconEvaluation of Genomic Applications in Practice and PreventionExternal Web Site Icon2009
Genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relativesExternal Web Site IconEvaluation of Genomic Applications in Practice and PreventionExternal Web Site Icon2009
Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test resultsExternal Web Site IconInternational Agency for Research on Cancer (IARC) Unclassified Genetic Variants Working GroupExternal Web Site Icon2008
Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?External Web Site IconEvaluation of Genomic Applications in Practice and PreventionExternal Web Site Icon2009

No hay comentarios:

Publicar un comentario